2022

The new combination antiretroviral drug NDF01 for HIV/AIDS has completed bioequivalence testing.

Received the bronze medal in the Talent Development Quality Management System (Enterprise Edition) of the Taiwan Technical and Quality Skills (TTQS) program by the Ministry of Labor's Bureau of Labor Development.

Completed the final data analysis of the Phase III human clinical trials for the biosimilar drug UB-851, a recombinant human erythropoietin.